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Systemic lupus erythematosus (SLE) is a complex autoimmune disease characterized
by the loss of tolerance to self-nuclear antigens. The symptoms of SLE, progression
of pathology and the array of autoantibodies present in the serum differ significantly
from patient to patient, which calls for a personalized approach to treatment. SLE is
polygenic and strongly influenced by gender, ethnicity, and environmental factors. Data
from genome-wide association studies suggests that polymorphisms in as many as
100 genes contribute to SLE susceptibility. Recent research has focused on genes
associated with Toll-like receptors (TLRs), type I interferons, immune regulation pathways,
and immune-complex clearance. TLR7 and TLR9 have been extensively studied using
lupus-prone mouse models. In multiple systems overexpression of TLR7 drives disease
progression but interestingly, a loss of TLR9 results in an almost identical phenotype. While
TLR7 overexpression has been linked to human SLE, the possible role of TLR9 in human
disease remains elusive. In the present review, we focus on TLR polymorphisms and
TLR expression in SLE patients and discuss their potential as biomarkers for individualized
treatment.
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INTRODUCTION
Systemic lupus erythematosus (SLE) is a chronic autoimmune
disease with a variety of clinical manifestations that differ from
patient to patient. The heterogeneity of the symptoms represents a
challenge for both diagnosis and treatment. While the diagnostic
criteria for SLE have evolved over the past decades (reviewed in
Yu et al., 2014), the treatment has remained largely symptomatic
using non-specific conventional therapies which include non-
steroidal anti-inflammatory drugs (NSAIDs), glucocorticoids,
hydroxychloroquine (HCQ), and immunosuppressants (Murphy
et al., 2013). In addition to their modest therapeutic effect, these
drugs have severe side effects leading to substantial morbidity
and mortality, resulting in a substantial economic burden to
many societies (Lau and Mak, 2009). In this short review, we
briefly discuss novel therapeutic agents and emerging immuno-
logical targets. We will focus on the burgeoning data on Toll-
like receptor (TLR) 7 and TLR9 in SLE and on the factors
that could influence their expression. We propose altered expres-
sion of TLR7/9 as a biomarker for identification of a subset
of SLE patients that might benefit from a targeted therapeutic
approach.
RECENT DEVELOPMENTS IN B CELL THERAPEUTICS
Recently, therapeutic avenues in SLE have pursued biologic drugs
which either deplete B cells or reduce their activity. Belimumab
(Benlysta®) is the only biological drug and the first therapeutic
in 50 years to be approved by the Federal Drug Administra-
tion (FDA) for the treatment of lupus. Belimumab is a human
monoclonal antibody (mAb) specific for B lymphocyte stimula-
tor (BLyS) protein/B cell activating factor (BAFF; Hahn, 2011).
Multicenter randomized controlled trials demonstrated a signif-
icant reduction in the Safety of Estrogen in Lupus Erythemato-
sus National Assessment–SLE Disease Activity Index (SELENA–
SLEDAI) score and risk of severe flares (Furie et al., 2011;
Navarra et al., 2011). Recent results also suggest that belimumab
may improve renal disease; however, further studies are needed
to demonstrate a benefit in patients with severe active renal
nephritis (Dooley et al., 2013). Based on the success of beli-
mumab, other B cell targeting therapies are being assessed in
clinical trials, including rituximab (anti-CD20), epratuzumab
(anti-CD22), blisibimod and tabalumab (anti-BLyS), and ataci-
cept [anti-BLyS/APRIL (A proliferation-inducing ligand); Kamal,
2014]. So far, the outcomes of B cell depletion with rituximab in
clinical trials have been disappointing, partially due to poor trial
design, problems with outcome measures and lack of long-term
follow-up (Looney et al., 2010; Murphy et al., 2013; Kamal, 2014).
In a randomized, double-blind, placebo-controlled Phase III trial
rituximab successfully depleted B cells in lupus nephritis patients
and decreased anti-dsDNA antibody levels, but failed to improve
renal disease (Rovin et al., 2012). Since human prospective studies
and mouse models have suggested a multi-step hypothesis to the
development of SLE, it is perhaps unsurprising that reducing
B cells has only moderate effects in end organ disease such as
nephritis (Arbuckle et al., 2003; Fairhurst et al., 2006; Kanta
and Mohan, 2009). Based on this hypothesis, the B cells have
a critical role in autoantibody production due to initial loss of
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tolerance. However, an additional amplification step within the
innate immune system is needed for the development of end
organ disease.
Accordingly, new therapeutic approaches which focus on tar-
geting innate immune cells are being developed (Figure 1).
TLR7 AS A TARGET FOR SLE THERAPY
IMMUNOLOGICAL EVIDENCE FOR TLRs IN SLE
The type I-interferon (IFN-I) gene signature is one of the main
immunological characteristics which was identified just over a
decade ago by multiple groups (Baechler et al., 2003; Bennett
et al., 2003; Crow, 2014). The increase in IFN-I-related genes
was identified in the peripheral blood monocytes (PBMCs) from
patients with SLE using gene expression profiling and has been
identified in the majority of pediatric SLE patients and in the
majority of adult SLE patients with active disease (Baechler et al.,
2003; Bennett et al., 2003). Interestingly, the gene expression
signature does not correlate with either elevated IFN-I levels in
SLE serum, which is detectable only in a fraction of patients,
or with elevated IFN-I mRNA (Blanco et al., 2001; Baechler
et al., 2003). The reason for this discrepancy might be the low
sensitivity of enzyme-linked immunosorbent assays (ELISAs) to
detect serum IFN-I and the migration of IFN-I-producing cells
to the tissues. However, there is also the possibility that the IFN-
I signature is caused by another stimulus aside from IFN-I itself
(Baechler et al., 2003; Bennett et al., 2003).
To overcome the limitations of serum IFN-I measurements
“IFN-I activity score” assays were developed by several groups
(Hua et al., 2006; Burgi Mde et al., 2012). These assays use serum
or plasma of patients and the activity score strongly correlates
with the titer of antinuclear autoantibodies (ANAs; Kirou et al.,
2005; Hua et al., 2006; Niewold et al., 2007). High IFN-I activity
score and the tendency to develop anti-ribonucleoprotein (RNP)
and anti-dsDNA antibodies appear to be independent risk fac-
tors for SLE, since healthy first-degree relatives of SLE patients
frequently display elevated IFN-I activity but no detectable ANAs
FIGURE 1 | A schematic representation of novel therapeutic
approaches in SLE involving the IFN-I signature, TLR7 and TLR9.
The choice of the appropriate treatment option should ideally be
based on the expression of relevant biomarkers in an individual
patient. Drugs that are currently in clinical development are listed with
the corresponding phase of the clinical trial (Clinicaltrials.gov, 2014).
IFIGs, interferon-inducible genes; HCQ, hydroxychloroquine; CQ,
chloroquine.
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(Niewold et al., 2007). The crucial connection between both traits
is nucleic acid-sensing by endosomal TLRs, which evolved as
sensors of foreign RNA and DNA (Blasius and Beutler, 2010;
Kawai and Akira, 2010). In SLE, where self-nucleic acids are asso-
ciated with autoantibodies in immune complexes (ICs), endo-
somal TLRs might become aberrantly activated in the absence
of foreign molecules (reviewed in Celhar et al., 2012). Multiple
in vitro studies in both mouse and human cells proved that
RNA/DNA-containing ICs activate TLR9 and TLR7 through B cell
receptor (BCR)-mediated internalization in B cells (Leadbetter
et al., 2002; Lau et al., 2005) and through Fc gamma receptor
(FcγR)-mediated internalization in dendritic cells (DCs; Boule
et al., 2004), plasmacytoid DCs (pDCs; Bave et al., 2003; Barrat
et al., 2005; Means et al., 2005; Vollmer et al., 2005; Lovgren
et al., 2006), macrophages (Henault et al., 2012), and neutrophils
(Garcia-Romo et al., 2011). Upon such activation, pDCs pro-
duce IFNα (Bave et al., 2003; Barrat et al., 2005; Means et al.,
2005; Vollmer et al., 2005; Lovgren et al., 2006), conventional
DCs produce cytokines (Boule et al., 2004) and neutrophils
release neutrophil extracellular traps (NETs; Garcia-Romo et al.,
2011). These findings highlight the central role of TLR7 and
TLR9 in the induction and modulation of immune responses
in SLE, and their association with the IFN-I signature (recently
reviewed in Kono et al., 2013; Shrivastav and Niewold, 2013;
Crow, 2014). Genome-wide association studies (GWAS) have
provided supporting evidence by identifying SLE susceptibility
variants in both TLR and IFN-I pathways (Rullo and Tsao,
2013).
GENETIC EVIDENCE: POLYMORPHISMS IN TLR7-ASSOCIATED
PATHWAYS
Overexpression of TLR7 causes severe lupus in multiple mouse
models of SLE (reviewed in Celhar et al., 2012). Male BXSB
lupus mice develop severe disease due to a translocation of a
segment near the pseudoautosomal region of the X chromosome
onto the Y chromosome, identified as the y-linked autoimmune
accelerating (yaa) locus (Pisitkun et al., 2006; Subramanian et al.,
2006). Among the duplicated genes, TLR7 was identified as the
major gene responsible for the development of severe disease
(Deane et al., 2007; Fairhurst et al., 2008; Santiago-Raber et al.,
2008). Genetically modified mouse models have proven to be
an indispensable tool for the study of single gene modifica-
tions. However, correlations with the highly genetically variable
human population are rarely straightforward. This is particularly
true for polygenic disorders such as SLE, where multiple genes
are associated with disease susceptibility (Rullo and Tsao, 2013;
Armstrong et al., 2014). Genomic data suggests that common
copy number variations (CNVs) similar to yaa are very rare
in human SLE (Conrad et al., 2010; Park et al., 2010; Shen
et al., 2010). Nevertheless, they may be an important risk factor
childhood-onset SLE, as recently shown in the Mexican popu-
lation (Garcia-Ortiz et al., 2010). Male patients with more than
one copy and female patients with greater than two copies of
TLR7 had a higher disease susceptibility and the TLR7 copy
number correlated with TLR7 mRNA expression levels (Garcia-
Ortiz et al., 2010). In addition to altered gene copy number, the
gene dosage of TLR7 can be altered in individuals affected by
aneuploidy. Indeed, SLE is more common in men affected by
conditions with additional X chromosomes, such as Klinefelter’s
syndrome (47,XXY; Ortiz-Neu and LeRoy, 1969; Dillon et al.,
2012).
Overall, however, it is unlikely that a single gene, in this case
TLR7, would have such a large impact. Consistent with this
theory, recent investigations have identified polymorphisms in
genes that are shared among TLR and IFN-I signaling pathways,
including the transcription factors interferon regulatory factor
(IRF) 5, IRF7, and IRF8 and components of the downstream
NFκB pathway, such as interleukin-1 receptor-associated kinase
1 (IRAK1) and tumor necrosis factor, alpha-induced protein 3
(TNFAIP3; Rullo and Tsao, 2013). Therefore, polymorphisms
in several genes could ultimately together lead to an excessive
response to RNA sensing by TLR7. Additionally, variants in
regulatory single nucleotide polymorphisms (SNPs) which bind
microRNA (miRNA), X-chromosome linked modifications and
induction of TLR7 expression by various infectious agents may be
involved in subgroups of SLE patients.
X-CHROMOSOME LINKED ALTERATIONS OF TLR7 EXPRESSION
Recent findings suggest that approximately 15% of genes on the
X chromosome escape X-linked inactivation and are thus bi-
allelicially expressed, ultimately increasing gene dosage (reviewed
in Berletch et al., 2011). X-linked genes are particularly interesting
in dissecting out causes of conditions that predominately affect
women, including autoimmune diseases and some viral infections
such as HIV and herpes simplex virus (HSV; Fish, 2008). Several
studies have attributed these sexual dimorphisms to differential
RNA-sensing by TLR7, since female immune cells produce higher
levels of IFNα upon stimulation with TLR7 ligands or virus-
derived RNA compared to male counterparts (Berghofer et al.,
2006; Meier et al., 2009; Torcia et al., 2012). The underling mecha-
nism for this sex bias is currently not clear. Berghofer et al. (2006)
found equivalent TLR7 mRNA expression in pDCs and B cells
from healthy males and females with no evidence of escaping X-
linked inactivation or involvement of estrogen receptor signaling.
However, these findings do not exclude escape from X-linked
inactivation in SLE patients.
EPIGENETIC FACTORS AND microRNA BINDING
It has now been established that miRNAs can act to fine tune TLR
signaling by targeting expression itself or by modulating adap-
tor molecules, downstream regulators and cytokines (reviewed
in O’Neill et al., 2011). Variants in the 3′ untranslated region
(UTR) regions may alter miRNAs binding and ultimately TLR7
expression and/or responsiveness. A large multi-centered and
multi-ethnic study identified such SNP in the 3′ UTR region of
TLR7 (rs3853839 (G/C)) as a risk factor for SLE (Shen et al.,
2010; Deng et al., 2013). The G-allele carriers have increased
TLR7 transcripts and are more likely to have anti-RNA associated
autoantibodies than C-allele carriers (Shen et al., 2010). The non-
risk C allele bears a binding site of microRNA-3148 (miR-3148),
which confers faster degradation of the transcript and thus lower
levels of TLR7 gene product (Deng et al., 2013).
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INDUCTION OF TLR7 EXPRESSION
Several studies have reported the induction of TLR7 transcription
in immune cells (B cells, eosinophils, monocytes, macrophages,
pDCs) following stimulation with various inflammatory agents,
including bacteria (Zarember and Godowski, 2002; Bourke et al.,
2003; Miettinen et al., 2008), viruses (Miettinen et al., 2001) CpG
(Hornung et al., 2002; Bourke et al., 2003), IFNα (Miettinen
et al., 2001; Sirén et al., 2005), and IFNγ (Miettinen et al., 2001;
Nagase et al., 2003). This increase in TLR7 during infection
may be part of a positive feedback mechanism to increase IFNα,
which is essential for a fast and robust anti-microbial response
(Rönnblom et al., 2006). It is possible that this pathway is dereg-
ulated in SLE patients and explains why many features of SLE
resemble a chronic viral infection in the absence of a detectable
virus (Crow, 2014). Indeed, upregulated TLR7 and TLR9 mRNA
expression have been reported in PBMCs from SLE patients and
levels correlate with the expression of IFNα (Komatsuda et al.,
2008; Lyn-Cook et al., 2014). Upregulation of TLR7, but not
other TLRs, has also been observed when healthy neutrophils
were cultured with sera from SLE patients with active disease
(Garcia-Romo et al., 2011). This may be due to IFNα present
in patient’s sera, since pre-treatment with purified IFNα resulted
in a similar response of increased TLR7. Furthermore, IFNα
increased susceptibility to anti-RNP antibody-induced NETo-
sis (Garcia-Romo et al., 2011). Consistent with these findings,
monocyte-derived macrophages produce IFNα upon TLR7/8 lig-
and stimulation only after pre-treatment with IFNα and sub-
sequent induction of TLR7 (Sirén et al., 2005). TLR7 may also
be induced by serum-derived ICs containing TLR7 ligands. A
recent study by Chauhan et al. (2013) showed that TLR7 was
preferentially increased in SLE patients with antibodies against
RNA-associated antigens, while TLR9 induction correlated with
anti-dsDNA antibody titers. Moreover, flu and synthetic TLR7
ligands have the capacity to induce early IFN-inducible genes in
pDCs independently of IFN-α production (Di Domizio et al.,
2009). Overall, accumulating data suggest that persistently higher
levels of TLR7 may lead to an acquired responsiveness in cells
which are normally unresponsive to TLR7 ligands. This is sup-
ported by the observation that pDCs are responsible for the
majority IFNα produced by healthy PBMCs, but account only
for 57% of IFNα produced by PBMCs from SLE patients (Blanco
et al., 2001).
TLR9 AS A TARGET FOR THERAPY FOR SLE
While TLR7 hyper-responsiveness in human SLE is consistent
with the TLR7-associated nephritis shown by mouse models, the
role of TLR9 remains controversial. Multiple mouse studies have
shown the importance of TLR9 expression in B cells for the
generation of anti-dsDNA, anti-chromatin, and anti-nucleosome
autoantibodies (Christensen et al., 2005, 2006; Lartigue et al.,
2006; Yu et al., 2006; Nickerson et al., 2010). However, the
deletion of TLR9 in these lupus-prone models did not lead to
amelioration, but rather to exacerbation of disease, suggesting
a protective/regulatory role of TLR9 in cells other than B cells.
Nonetheless, the manifestation of the disease in TLR9-deficient
mice was dependent on TLR7 expression (Nickerson et al.,
2010).
Increases in TLR9 expression have been shown in PBMCs from
SLE patients and levels usually correlate with IFNα expression
and anti-dsDNA antibodies (Komatsuda et al., 2008; Mu et al.,
2012; Chauhan et al., 2013; Lyn-Cook et al., 2014). Additionally,
B cells and monocytes from patients with active disease express
higher TLR9 levels compared to patients with inactive disease
(Papadimitraki et al., 2006; Nakano et al., 2008). An increase in
the frequency of TLR9-expressing B cells, but not monocytes, cor-
related with anti-dsDNA antibodies (Papadimitraki et al., 2006).
These results suggest that, similarly to murine studies, increased
TLR9 expression in B cells may be involved in autoantibody
production, especially anti-dsDNA
However, paradoxically, the increased expression of TLR9 does
not lead to increased responsiveness to TLR9 ligands. Despite an
increase in TLR9 on B cells and BDCA3+ DCs from patients
with severe disease, cells were less activated and hyporesponsive
to TLR9 stimulation (Zorro et al., 2009). Similarly, despite an
increased TLR9 expression in SLE PBMCs, TLR9-induced IFN-
α production was markedly reduced (Kwok et al., 2008). This
desensitization has been directly attributed to HCQ treatment
(Kwok et al., 2008; Sacre et al., 2012). However, in patients
not taking HCQ, alterations in downstream TLR9-signaling or
induction of negative regulators may be involved (Kwok et al.,
2008; Zorro et al., 2009).
Limited data is available on the effect of decreased TLR9
expression in human SLE. A recent study conducted in a cohort
of Danish SLE patients found significantly decreased TLR9 mRNA
expression in lupus PBMCs, which did not correlate with dsDNA
antibody titers (Laska et al., 2014). It would be interesting to
further identify the main cell type within the PBMCs responsible
for the downregulation and assess the responsiveness to TLR9
ligands in this cohort.
Overall, further research is required to establish the role of
TLR9 in mediating the progression of benign autoimmunity to
severe disease.
TLR9 POLYMORPHISMS
Several TLR9 polymorphisms have been associated with SLE,
particularly in patients of Asian or European ancestry (Tao et al.,
2007; Xu et al., 2009; Lu et al., 2011; dos Santos et al., 2012; Huang
et al., 2012; Piotrowski et al., 2013; Laska et al., 2014). However,
these results were not confirmed by other studies or by a recent
meta-analysis (Hur et al., 2005; Ng et al., 2005; De Jager et al.,
2006; Yang et al., 2012). Similarly, as mentioned earlier for TLR7,
polymorphisms in a single gene are not very likely to recapitulate
a polygenic disease like SLE. Additional genetic variants in TLR9-
downstream signaling pathways, regulators of TLR signaling and
epigenetic modifications should also be considered and need
further examination.
DEVELOPMENT OF NOVEL THERAPEUTICS FOR SLE
NOVEL THERAPIES DIRECTED TOWARD IFNα
IFNα signaling may be suppressed by several strategies: direct
neutralization by an anti-IFNα mAb, suppression of the IFN-I sig-
nature using an anti-IFNα receptor (IFNAR) antibody, or immu-
nization to achieve endogenous anti-IFNα production (reviewed
in Crow, 2014). Three anti-IFN-α mAbs, sifalimumab, AGS-
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009, and rontalizumab, have achieved safety and dose-dependent
reduction of IFN-I signature in Phase I SLE trials (Yao et al., 2009;
Merrill et al., 2011; Petri et al., 2013; Stohl, 2013). Furthermore,
a Phase II trial has shown that rontalizumab decreased the inci-
dence of flares and reduced prednisone dosage in a subgroup
of patients who had a low IFN-I signature at baseline (Stohl,
2013).
Targeting the IFNAR with MEDI-546, a fully human mAb
against huIFNAR, achieved success in Phase I trials for systemic
sclerosis (SSc; Wang et al., 2013). Pharmacogenomics and transla-
tional simulations were used to build a model to predict responses
to MEDI-546 in SLE patients and facilitated the progression
of this candidate molecule to a Phase II trial (Wang et al.,
2013).
Immunization with human (hu) IFNalpha2b kinoid (IFN-K)
generates endogenous polyclonal antibodies directed against all
13 subtypes of huIFNα (Mathian et al., 2011). The results from
the first clinical study show that IFN-K is well tolerated and
significantly reduces the IFN-I signature in IFN signature-positive
patients (Lauwerys et al., 2013).
An additional approach is the blockage of BDCA-2 expressed
on the surface of pDCs. Anti-BDCA-2 mAb successfully inhib-
ited IFN-α production from healthy donors and SLE patients
(Dzionek et al., 2001; Blomberg et al., 2003). A patent application
has recently been submitted for an anti-BDCA-2 antibody in
the context of preventing or treating pathological conditions
involving pDC activation (De and Fournier, 2012).
TLR INHIBITION IN SLE
Several compounds that bind endosomal TLR7 and/or TLR9
activation have been developed with the goal to inhibit IFNα
production and activation of autoimmune B cells (Barrat and
Coffman, 2008; Kandimalla et al., 2013). This approach success-
fully ameliorated disease in lupus-prone mice but it needs further
clinical evaluation (Barrat et al., 2007). IMO-3100, a TLR7/9
antagonist, and IMO-8400, a TLR7/8/9 antagonist, suppressed
inflammation in a mouse model of psoriasis (Suarez-Farinas et al.,
2013). Both compounds were well tolerated by healthy adults and
are now undergoing Phase 2 trials in psoriasis patients (Clinical-
trials.gov, 2014). It is important to note that the therapeutic value
of the standard SLE care drugs HCQ and chloroquine have been
attributed to indirect inhibition of TLR7 and TLR9, through their
inhibitory action on endosomal acidification which is necessary
for TLR7/9 activation (Sacre et al., 2012).
Finally, miRNA-based therapies and therapeutics design to
degrade RNA may also represent potential treatment options in
specific groups of SLE patients (Deng et al., 2013; Sun et al., 2013).
CONCLUSION
Advances in the understanding of the innate immune system have
revolutionized the development of novel SLE therapies. Owing
to the heterogeneous nature of the clinical manifestations, much
thought is being given to a stratification of lupus patients based
on clinical symptoms and immunological dysfunctions, target-
ing disease development in a personalized medicine approach.
This is particularly important for the design of clinical trials,
where the correct recruitment and sub-grouping of patients may
directly impact the outcome measures. Pharmacogenomic and
pharmacogenetic studies will ultimately be essential to identify
patients that will most likely benefit from a specific treatment.
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